SRSF2 and acute myeloid leukemia: Because AML samples from patients with concurrent SRSF2 and RUNX1 mutations were resistant to CHK1 inhibition (Figure 2A), we tested whether Runx1 depletion confers CHK1-inhibitor resistance in splicing-factor–mutant mouse hematopoietic progenitors.